CTOs on the Move

KSQ Therapeutics

www.ksqtx.com

 
KSQ Therapeutics has built an industry-leading genome-scale precision functional genomics platform, called CRISPRomics, to pinpoint therapeutic nodes that directly correlate genomic function to disease with unprecedented certainty and speed. The company is deploying CRISPRomics for novel drug development across broad therapeutic areas and is currently advancing a proprietary pipeline of tumor- and immune-focused drug candidates. KSQ was founded by thought leaders in the field of functional genomics and pioneers of CRISPR screening technologies, and the company is located in Cambridge, Massachusetts.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ksqtx.com
  • 4 Maguire Road
    Lexington, MA USA 02421
  • Phone: 617.674.9150

Executives

Name Title Contact Details
Thomas Leitch
Chief Technology Officer Profile

Funding

KSQ Therapeutics raised $76M on 10/02/2017
KSQ Therapeutics raised $80M on 09/28/2018

Similar Companies

Meta Nutrition

Meta Nutrition - The platform that knows what to eat!

Curai Health

Providing the world`s best healthcare to everyone

North Central Connecticut EMS Council Inc

North Central Connecticut EMS Council Inc is a Hartford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Duke University Health System

As a world-class academic and health care system, Duke Health strives to transform medicine and health locally and globally through innovative scientific research, rapid translation of breakthrough discoveries, educating future clinical and scientific leaders, advocating and practicing evidence-based medicine to improve community health, and leading efforts to eliminate health inequalities.

Nymox

NYMOZARFEX (TM) is given in an in-office procedure that is administered in a few minutes without need of anesthesia or analgesia. The drug has been tested in clinical trials involving overall more than 1750 patients with over 1600 injections administered including over 1200 Fexapotide administrations. Fexapotide has led to significant long-term improvements and has shown an excellent safety profile without the side effects normally associated with existing BPH treatments.